Hostname: page-component-8448b6f56d-xtgtn Total loading time: 0 Render date: 2024-04-18T13:24:06.849Z Has data issue: false hasContentIssue false
  • English
  • Français

Complementary medicines in psychiatry

Review of effectiveness and safety

Published online by Cambridge University Press:  02 January 2018

Ursula Werneke ,
Trevor Turner  and
Stefan Priebe
Ursula Werneke*
Affiliation:
Division of Health Service Research, Institute of Psychiatry, and Division of Psychiatry Homerton University Hospital
Trevor Turner
Affiliation:
Division of Psychiatry, Homerton University Hospital
Stefan Priebe
Affiliation:
Unit for Social and Community Psychiatry, Barts and The London, NHS Trust, Queen Mary School of Medicine and Dentistry, London, UK
*
Dr Ursula Werneke, Division of Psychiatry, Homerton University Hospital, East Wing, Homerton Row, London E9 6SR, UK. E-mail: UrsulaWerneke@elcmht.nhs.uk
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background

The use of complementary medicines in those with mental health problems is well documented. However, their effectiveness is often not established and they may be less harmless than commonly assumed.

Aims

To review the complementary medicines routinely encountered in psychiatric practice, their effectiveness, potential adverse effects and interactions.

Method

Electronic and manual literature search on the effectiveness and safety of psychotropic complementary medicines.

Results

Potentially useful substances include ginkgo and hydergine as cognitive enhancers, passion flower and valerian as sedatives, St John's wort and sadenosylmethionine as antidepressants, and selenium and folate to complement antidepressants. The evidence is less conclusive for the use of omega-3 fatty acids as augmentation treatment in schizophrenia, melatonin for tardive dyskinesia and 18-methoxycoronaridine, an ibogaine derivative, for the treatment of cocaine and heroin addiction.

Conclusions

Systematic clinical trials are needed to test promising substances. Meanwhile, those wishing to take psychotropic complementary medicines require appropriate advice.

Type
Review Article
Information
The British Journal of Psychiatry , Volume 188 , Issue 2 , February 2006 , pp. 109 - 121
Copyright
Copyright © 2006 The Royal College of Psychiatrists 

Footnotes

Declaration of Interest

None.

References

Ahlemeyer, B. & Krieglstein, J. (2003) Neuroprotective effects of Ginkgo biloba extract. Cellular and Molecular Life Sciences, 60, 1779–1792.Google Scholar
Akhondzadeh, S., Naghavi, H. R., Vazirian, M., et al (2001a) Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. Journal of Clinical Pharmacy and Therapeutics, 26, 363–367.CrossRefGoogle ScholarPubMed
Akhondzadeh, S., Kashani, L., Mobaseri, M., et al (2001b) Passionflower in the treatment of opiates withdrawal: a double-blind randomized controlled trial. Journal of Clinical Pharmacy and Therapeutics, 26, 369–373.Google Scholar
Alderman, C. P. & Kiepfer, B. (2003) Complementary medicine use by psychiatry patients of an Australian hospital. Annals of Pharmacotherapy, 37, 1779–1784.Google Scholar
Amenta, F., Cavallotti, C., Franch, F., et al (1989) Muscarinic cholinergic receptors in the hippocampus of the aged rat: effects of long-term hydergine administration. Archives Internationales de Pharmacodynamie et de Thérapie, 297, 225–234.Google Scholar
Benjamin, J., Muir, T., Briggs, K., et al (2001) A case of cerebral haemorrhage – can Ginkgo biloba be implicated? Postgraduate Medical Journal, 77, 112–113.Google Scholar
Benton, D. (2002) Selenium intake, mood and other aspects of psychological functioning. Nutrition and Neurosciences, 5, 363–374.CrossRefGoogle ScholarPubMed
Benton, D. & Cook, R. (1991) Selenium supplementation improves mood in a double-blind crossover trial. Biological Psychiatry, 29, 1092–1098.CrossRefGoogle Scholar
Birks, J., Grimley Evans, J. & Van Dongen, M. (2002) Gingko biloba for cognitive impairment and dementia. Cochrane Library, Issue 2. Oxford: Update Software.Google Scholar
Boerner, R. J., Sommer, H., Berger, W., et al (2003) Kava-Kava extract L1150 is as effective as opipramol and buspirone in generalised anxiety disorder – an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients. Phytomedicine, 10 (suppl.), 38–49.Google Scholar
Bottiglieri, T., Laundy, M., Crellin, R., et al (2000) Homocysteine, folate, methylation, and monoamine metabolism in depression. Journal of Neurology, Neurosurgery and Psychiatry, 69, 228–232.Google Scholar
Bowden, C. L. (2001) Novel treatments for bipolar disorder. Expert Opinion in Investigating Drugs, 10, 661–671.Google Scholar
Bressa, G. M. (1994) S-adenosyl-1-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurologica Scandinavica, 154 (suppl.), 7–14.Google Scholar
Brown, B. G., Zhao, X. Q., Chait, A., et al (2001) Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. New England Journal of Medicine, 29, 1583–1592.Google Scholar
Brugha, T., Rampes, H. & Jenkins, R. (2004) Surely you take complementary and alternative medicines? Psychiatric Bulletin, 28, 36–39.CrossRefGoogle Scholar
Cardinali, D. P., Gvozdenovich, E., Kaplan, M. R., et al (2002) A double blind-placebo controlled study on melatonin efficacy to reduce anxiolytic benzodiazepine use in the elderly. Neuroendocrinology Letters, 23, 55–60.Google Scholar
Carman, J. S., Post, R. M., Buswell, R., et al (1976) Negative effects of melatonin on depression. American Journal of Psychiatry, 133, 1181–1186.Google Scholar
Chatterjee, S. S., Nolder, M., Koch, E., et al (1998) Antidepressant activity of hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry, 31 (suppl.), 7–15.CrossRefGoogle ScholarPubMed
Chevallier, A. (1996) The Encyclopedia of Medicinal Plants. London: Dorling Kindersley.Google Scholar
Coffin, A. I. (1845) Botanic Guide to Health and Natural Pathology of Diseases. London: J. Caudwell.Google Scholar
Cohen, M. H. & Eisenberg, D. M. (2002) Potential physician malpractice liability associated with complementary and integrative medicinal therapies. Annals of Internal Medicine, 136, 596–603.Google Scholar
Committee on Safety of Medicines & Medicines Control Agency (2000) Reminder: St John's wort (Hypericum perforatum) interactions. Current Problems in Pharmacovigilance, 26, 6–7.Google Scholar
Corrigan, J. J. Jr (1982) The effect of vitamin E on warfarin-induced vitamin K deficiency. Annals of the New York Academy of Sciences, 393, 361–368.CrossRefGoogle ScholarPubMed
Cott, J. M. (1997) In vitro receptor binding and enzyme inhibition by hypericum perforatum extract. Pharmacopsychiatry, 30 (suppl.), 108–112.Google Scholar
De Vry, J., Maurel, S., Schreiber, R., et al (1999) Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism. European Neuropsychopharmacology, 9, 61–68.Google Scholar
Delle Chiaie, R., Pancheri, P. & Scapicchio, P. (2002) Efficacy and tolerability of oral andintramuscular S-adenosyl-L-methionine 1, 4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition, 76 (suppl.), 1172S–1176S.CrossRefGoogle ScholarPubMed
Dhawan, K., Kumar, S. & Sharma, A. (2002a) Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linnaeus in mice: a possible therapy for cannabinoid addiction. Journal of Pharmacy and Pharmacology, 54, 875–881.Google Scholar
Dhawan, K., Kumar, S. & Sharma, A. (2002b) Nicotine reversal effects of the benzoflavone moiety from Passiflora incarnata Linneaus in mice. Addiction Biology, 7, 435–441.Google Scholar
Dhawan, K., Dhawan, S. & Chhabra, S. (2003) Attenuation of benzodiazepine dependence in mice by a tri-substituted benzoflavone moiety of Passiflora incarnata Linneaus: a non-habit forming anxiolytic. Journal of Pharmacy and Pharmacological Science, 6, 215–222.Google ScholarPubMed
Diaper, A. & Hindmarch, I. (2004) Adouble-blind, placebo-controlled investigation of the effects of two doses of a valerian preparation on the sleep, cognitive and psychomotor function of sleep-disturbed older adults. Phytotherapy Research, 18, 831–836.Google Scholar
Dinh, L. D., Simmen, U., Bueter, K. B., et al (2001) Interaction of various Piper methysticum cultivars with CNS receptors in vitro. Planta Medica, 67, 306–311.CrossRefGoogle ScholarPubMed
Dorn, M. (2000) Efficacy and tolerability of Baldrian versus oxazepam in non-organic and non-psychiatric insomniacs: a randomised, double blind, clinical comparative study. Forschende Komplementarmedizin und Klassische Naturheilkunde, 7, 79–84.Google Scholar
Dravid, A. R. (1983) Deficits in cholinergic enzymes and muscarinic receptors in the hippocampus and striatum of senescent rats: effectofchronic hydergine treatment. Archives Internationales Pharmacodynamie et de Therapie, 264, 195–202.Google Scholar
Eisenberg, D. M., Kessler, R. C., Foster, C., et al (1993) Unconventional medicinein the United States. Prevalence, costs and pattern of use. New England Journal of Medicine, 328, 246—252.Google Scholar
Ernst, E. (2002) “Flower remedies”: a systematic review of the clinical evidence. Wiener Klinische Wochenschrift, 30, 963–966.Google Scholar
Ernst, E. & Cassileth, B. R. (1999) Howuseful are unconventional cancer treatments? European Journal of Cancer, 35, 1608–1613.Google Scholar
Fava, M., Giannelli, A., Rapisarda, V., et al (1995) Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine. Psychiatry Research, 56, 295–297.CrossRefGoogle ScholarPubMed
Fisher, A. A., Purcell, P. & LeCouteur, D. G. (2000) Toxicity of Passiflora incarnata L. Journal of Clinical Toxicology, 38, 63–66.Google Scholar
Food Standards Agency. Expert Group on Vitamins and Minerals (2003) Safe Upper Levels for Vitamins and Minerals. http://www.foodstandards.gov.uk Google Scholar
Friedel, H. A., Goa, K. L. & Benfield, P. (1989) S-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs, 38, 389–416.Google Scholar
Fugh-Berman, A. (2000) Herb—drug interactions. Lancet, 355, 134–138.CrossRefGoogle ScholarPubMed
Glick, S. D., Maisonneuve, I. M. & Dickinson, H. A. (2000) 18-MC reduces methamphetamine and nicotine self-administration in rats. Neuroreport, 11, 2013–2015.CrossRefGoogle ScholarPubMed
Haag, M. (2003) Essential fatty acids and the brain. Canadian Journal of Psychiatry, 48, 195–203.Google Scholar
Hamilton, M. (1967) Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology, 6, 278–296.Google Scholar
Hawkes, W. C. & Hornbostel, L. (1996) Effects of dietary selenium on mood in healthy men living in a metabolic research unit. Biological Psychiatry, 39, 121–128.Google Scholar
Herxheimer, A. & Petrie, K. J. (2003) Melatonin for the prevention and treatment of jet lag. Cochrane Library, issue 4. Oxford: Update Software.Google Scholar
Houghton, P. J. (1999) The scientific basis for the reputed activity of Valerian. Journal of Pharmacy and Pharmacology, 51, 505–512.Google Scholar
Itil, T. M., Ahmed, I., Kunitz, A., et al (1998) The pharmacological effects of ginkgo biloba, a plant extract, on the brain of dementia patients in comparison with tacrine. Psychopharmacology Bulletin, 34, 391–397.Google Scholar
Jaroszewski, J. W., Olafsdottir, E. S., Wellendorph, P., et al (2002) Cyanohydrin glycosides of Passiflora: distribution pattern, a saturated cyclopentane derivative from P. guatemalensis, and formation of pseudocyanogenic alpha-hydroxyamides as isolation artifacts. Phytochemistry, 59, 501–511.Google Scholar
Joy, C. B., Mumby-Croft, R. & Joy, L. A. (2003) Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Library, issue 4. Oxford: Update Software.Google Scholar
Jussofie, A., Schmiz, A. & Hiemke, C. (1994) Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology, 116, 469–474.CrossRefGoogle ScholarPubMed
Kanowski, S. & Hoerr, R. (2003) Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry, 36, 297–303.Google Scholar
Kessler, R. C., Soukup, J., Davis, R. B., et al (2001) The use of complementary and alternative therapies to treat anxiety and depression in the United States. American Journal of Psychiatry, 158, 289–294.Google Scholar
Keung, W. M. (1993) Biochemical studies of a new class of alcohol dehydrogenase inhibitors from Radix puerariae. Alcoholism, Clinical and Experimental Research, 17, 1254–1260.Google Scholar
Klepser, T. B. & Klepser, M. E. (1999) Unsafe and potentially safe herbal therapies. American Journal of Health-System Pharmacy, 56, 125–138.Google Scholar
Knaudt, P. R., Connor, K. M., Weisler, R. H., et al (2001) Alternative therapy use by psychiatric outpatients. Journal of Nervous and Mental Disease, 187, 692–695.Google Scholar
Krasowski, M. D., McGehee, D. S. & Moss, J. (1997) Natural inhibitors of cholinesterases: implications for adverse drug reactions. Canadian Journal of Anaesthesia, 44, 525–534.Google Scholar
Lee, B. M., Lee, S. K. & Kim, H. S. (1998) Inhibition of oxidative DNA damage, 8-OHdG, and carbonyl contents in smokers treated with antioxidants (vitamin E, vitamin C, beta-carotene and red ginseng). Cancer Letters, 132, 219–227.Google Scholar
Lehrl, S. (2004) Clinical efficacy of kava extract WS 1490 in sleep disturbances associated with anxiety disorders. Results of a multicenter, randomized, placebo-controlled, double-blind clinical trial. Journal of Affective Disorders, 78, 101–110.Google Scholar
Le Poncin-Lafitte, M., Rapin, J. R., Duterte, D., et al (1985) Learning and cholinergic neurotransmission in old animals: the effect of Hydergine. Pharmacology, 16 (suppl), 57–63.Google Scholar
Lewis, R., Wake, G., Court, G., et al (1999) Non-ginsenoside nicotinic activity in ginseng species. Phytotherapy Research, 13, 59–64.Google Scholar
Liede, K. E., Haukka, J. K., Saxen, L. M., et al (1998) Increased tendency towards gingival bleeding caused by joint effect of alpha-tocopherol supplementation and acetylsalicylic acid. Annals of Medicine, 30, 542–546.Google Scholar
Lin, R. C. & Li, T. K. (1998) Effects of isoflavones on alcohol pharmacokinetics and alcohol-drinking behavior in rats. American Journal of Clinical Nutrition, 68 (suppl.), 1512S–1515S.Google Scholar
Linde, K., Ramirez, G., Mulrow, C. D., et al (1996) St John's wort for depression – an overview and metaanalysis of the randomised clinical trials. BMJ, 313, 253–258.Google Scholar
Linde, K., Berner, M., Egger, M., et al (2005) St John's wort for depression. Meta-analysis of randomised controlled trials. British Journal of Psychiatry, 186, 99–107.Google Scholar
Lohr, J. B., Kuczenski, R. & Niculescu, A. B. (2003) Oxidative mechanisms and tardive dyskinesia. CNS Drugs, 17, 47–62.Google Scholar
Maclennan, K. M., Darlington, C. L. & Smith, P. F. (2002) The CNS effects of Ginkgo biloba extracts and ginkgolide B. Progress in Neurobiology, 67, 235–257.CrossRefGoogle ScholarPubMed
Macmahon, K. M. A., Broomfield, N. M. & Espie, C. A. (2005) A systematic review of the effectiveness of oral melatonin for adults (18 to 65 years. with delayed sleep phase syndrome and adults (18 to 65 years. with primary insomnia. Current Psychology Reviews, 1, 103–113.Google Scholar
Maisonneuve, I. M. & Glick, S. D. (2003) Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment. Pharmacology, Biochemistry and Behavior, 75, 607–618.Google Scholar
Malamud, W., Barton, W. E., Fleming, A. M., et al (1957) The evaluation of the effects of derivatives of Rauwolfia in the treatment of schizophrenia. American Journal of Psychiatry, 114, 193–200.CrossRefGoogle ScholarPubMed
Marangell, L. B., Martinez, J. M., Zboyan, H. A., et al (2003) A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. American Journal of Psychiatry, 160, 996–998.CrossRefGoogle ScholarPubMed
Markstein, R. (1985) Hydergine: interaction with the neurotransmitter systems in the central nervous system. Journal of Pharmacology, 16 (suppl.), 1–17.Google Scholar
Mash, D. C., Staley, J. K., Pablo, J. P., et al (1995) Properties of ibogaine and its principal metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex. Neuroscience Letters, 192, 53–56.Google Scholar
Mathews, J. M., Etheridge, A. S. & Black, S. R. (2002) Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metabolism and Disposition, 30, 1153–1157.CrossRefGoogle ScholarPubMed
Matthews, M. K. Jr (1998) Association of Ginkgo biloba with intracerebral hemorrhage. Neurology, 50, 1933–1934.Google Scholar
Matthews, S. C., Camacho, A., Lawson, K., et al (2003) Use of herbal medications among 200 psychiatric outpatients: prevalence, patterns of use, and potential dangers. General Hospital Psychiatry, 25, 24–26.CrossRefGoogle ScholarPubMed
Medical Economics (2000) PDR (Physicians’ Desk Reference) for Herbal Medicines (2nd edn). Montvale, NJ: Medical Economics Company.Google Scholar
Meseguer, E., Taboada, R., Sanchez, V., et al (2002) Life-threatening parkinsonism induced by kava-kava. Movement Disorders, 17, 195–196.Google Scholar
Miller, L. G. (1989) Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Archives of Internal Medicine, 158, 2200–2211.Google Scholar
Mischoulon, D. & Fava, M. (2002) Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. American Journal of Clinical Nutrition, 76 (suppl), 1158S–1161S.Google Scholar
Morris, M., Fava, M. & Jaques, P. F. (2003) Depression and folate status in the US population. Psychotherapie Psychosomatik, 72, 80–87.Google Scholar
Müller, W. E., Singer, A., Wonnemann, M., et al (1998) Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry, 31 (suppl), 16–21.Google Scholar
Munoz-Hoyos, A., Sanchez-Forte, M., Molina-Carballo, A., et al (1998) Melatonin's role as an anticonvulsant and neuronal protector: experimental and clinical evidence. Journal of Child Neurology, 13, 501–509.Google Scholar
Natural Medicines Comprehensive Database (2004a) http://www.naturaldatabase.com. Product search: Kava.Google Scholar
Natural Medicines Comprehensive Database (2004b) http://www.naturaldatabase.com. Product search: Iodine.Google Scholar
Natural Medicines Comprehensive Database (2004c) http://www.naturaldatabase.com. Product search: Selenium.Google Scholar
Natural Medicines Comprehensive Database (2004d) http://www.naturaldatabase.com. Product search: Folic acid.Google Scholar
Natural Medicines Comprehensive Database (2004e) http://www.naturaldatabase.com. Product search: Indian snakeroot.Google Scholar
Natural Medicines Comprehensive Database (2004f) http://www.naturaldatabase.com. Product search: Iboga.Google Scholar
Natural Medicines Comprehensive Database (2004g) http://www.naturaldatabase.com. Product search: Kudzu.Google Scholar
Neary, J. T. & Bu, Y. (1999) Hyperforin inhibits uptake of serotonin and norepinephrine in astrocytes. Brain Research, 816, 358–363.Google Scholar
Nemets, B., Stahl, Z. & Belmaker, R. H. (2002) Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. American Journal of Psychiatry, 159, 477–479.Google Scholar
Oken, B. S., Storzbach, D. M. & Kaye, J. A. (1998) The efficacy of ginkgo biloba on cognitive function in Alzheimer disease. Archives of Neurology, 55, 1409–1415.Google Scholar
Olde Rikkert, M. G. & Rigaud, A. S. (2001) Melatonin in elderly patients with insomnia. A systematic review. Gerontology and Geriatrics, 34, 491–497.Google Scholar
Olin, J., Schneider, L., Novit, A., et al (2001) Hydergine for dementia. Cochrane Library issue 4. Oxford: Update Software.Google Scholar
Ondrizek, R. R., Chan, P. J., Patton, W. C., et al (1999) Inhibition of human sperm motility by specific herbs used in alternative medicine. Journal of Assisted Reproduction and Genetics, 16, 87–91.Google Scholar
Overstreet, D. H., Keung, W. M., Rezvani, A. H., et al (2003a) Herbal remedies for alcoholism: promises and possible pitfalls. Alcoholism, Clinical and Experimental Research, 27, 177–185.Google Scholar
Overstreet, D. H., Kralic, J. E., Morrow, A. L., et al (2003b) NPI- 031G (puerarin) reduces anxiogenic effects of alcohol withdrawal or benzodiazepine inverse or 5-HT(2C) agonists. Pharmacology, Biochemistry and Behavior, 75, 619–625.CrossRefGoogle ScholarPubMed
Pancheri, P., Scapicchio, P. & Chiaie, R. D. (2002) A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1, 4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology, 5, 287–294.Google Scholar
Perovic, S. & Müller, W. E. (1995) Pharmacological profile of hypericin extract. Effect on serotonin reuptake by postsynaptic receptors. Arzneimittelforschung, 45, 1145–1148.Google Scholar
Pittler, M. H. & Ernst, E. (2003) Kava extract for treating anxiety. Cochrane Library issue 4. Oxford: Update Software.Google Scholar
Poyares, D. R., Guilleminault, C., Ohayon, M. M., et al (2002) Can valerian improve the sleep of insomniacs after benzodiazepine withdrawal? Progress in Neuropsychopharmacology and Biological Psychiatry, 26, 539–545.Google Scholar
Rezvani, A. H., Overstreet, D. H., Yang, Y., et al (1997) Attenuation of alcohol consumption by a novel nontoxic ibogaine analogue (18-methoxycoronaridine) in alcohol-preferring rats. Pharmacology, Biochemistry and Behavior, 58, 615–619.Google Scholar
Rezvani, A. H., Overstreet, D. H., Yang, Y., et al (1999) Attenuation of alcohol intake by extract of Hypericum perforatum (St. John's Wort) in two different strains of alcohol-preferring rats. Alcohol and Alcoholism, 34, 699–705.Google Scholar
Rezvani, A. H., Overstreet, D. H., Perfumi, M., et al (2003) Plant derivatives in the treatment of alcohol dependency. Pharmacology, Biochemistry and Behavior, 75, 593–606.Google Scholar
Roberts, C. G. & Ladenson, P. W. (2004) Hypothyroidism. Lancet, 363, 793–803.Google Scholar
Roder, C., Schaefer, M. & Leucht, S. (2004) Metaanalysis of effectiveness and tolerability of treatment of mild to moderate depression with St. John's Wort. Fortschritte der Neurologie Psychiatrie, 72, 330–343.Google Scholar
Sano, M., Ernesto, C., Thomas, R. G., et al (1997) A controlled trial of selegeline, alpha-tocopherol or both as treatment for Alzheimers disease. New England Journal of Medicine, 336, 1216–1222.Google Scholar
Schelosky, L., Raffauf, C. & Jendroska, K. (1995) Kava and dopamine antagonism. Journal of Neurology, Neurosurgery and Psychiatry, 58, 639–640.CrossRefGoogle ScholarPubMed
Schmitz, M. & Jackel, M. (1998) Comparative study for assessing quality of life of patients with exogenous sleep disorders (temporary sleep onset and sleep interruption disorders) treated with ahops-valerian preparation and a benzodiazepine drug. Wiener Medizinische Wochenschrift, 148, 291–298.Google Scholar
Schreiter-Gasser, U. & Gasser, T. (2001) A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia. Fortschritte der Medizin Originalien, 119, 135–136.Google Scholar
Shamir, E., Barak, Y., Plopsky, I., et al (2000) Is melatonin treatment effective for tardive dyskinesia? Journal of Clinical Psychiatry, 61, 556–558.Google Scholar
Shamir, E., Barak, Y. & Shalman, I. (2001) Melatonin treatment for tardive dyskinesia: double-blind, placebo-controlled, crossover study. Archives of General Psychiatry, 58, 1049–1052.Google Scholar
Shebek, J. & Rindone, J. P. (2000) A pilot study exploring the effect of kudzu root on the drinking habits of patients with chronic alcoholism. Journal of Alternative and Complementary Medicine, 6, 45–48.Google Scholar
Sheppard, S. G. (1994) A preliminary investigation of ibogaine: case reports and recommendations for further study. Journal of Substance Abuse and Treatment, 11, 379–385.Google Scholar
Sher, L. (2001) Role of thyroid hormones in the effects of selenium on mood, behavior, and cognitive function. Medical Hypotheses, 57, 480–483.Google Scholar
Singer, C., Tractenberg, R. E., Kaye, J., et al (2003) Alzheimer's Disease Cooperative Study. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep, 26, 893–901.Google Scholar
Soares, K. V. S. & McGrath, J. J. (2001) Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Library issue 4. Oxford: Update Software.Google Scholar
Spinella, M. (2001) Psychotherapeutic herbs. In The Psychopharmacology of Herbal Medicine p. 278. Cambridge, MA: MIT Press.Google Scholar
Staley, J. K., Ouyang, Q. & Pablo, J. (1996) Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine. Psychopharmacology, 127, 10–18.Google Scholar
Stevinson, C. & Ernst, E. (2000) Valerian for insomnia: a systematic review of randomized clinical trials. Sleep Medicine, 1, 91–99.Google Scholar
Stoll, A. L., Severus, W. E., Freeman, M. P., et al (1999) Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Archives of General Psychiatry, 56, 407–412.Google Scholar
Su, K. P., Huang, S. Y., Chiu, C. C., et al (2003) Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. European Neuropsychopharmacology, 13, 267–271.Google Scholar
Szegedi, A., Kohnen, R., Dienel, A., et al (2005) Acute treatment of moderate to severe depression with hypericum extract WS5570 (St John's wort): randomised controlled double blind non-inferiority trial against paroxetine. BMJ, 330, 503–506.Google Scholar
Tabet, N., Birks, J. & Grimley Evans, J. (2000) Vitamin E for Alzheimer's disease. Cochrane Library issue 4. Oxford: Update Software.Google Scholar
Tang, F., Nag, S., Shiu, S. Y., et al (2002) The effects of melatonin and Ginkgo biloba extract on memory loss and choline acetyltransferase activities in the brain of rats infused intracerebroventricularly with beta-amyloid. Life Sciences, 71, 2625–2631.Google Scholar
Taylor, M. J., Carney, S., Geddes, J., et al (2004) Folate for depressive disorders. Cochrane Library, issue 1. Oxford: Update Software.Google Scholar
Teufel-Mayer, R. & Gleitz, J. (1997) Effect of long term administration of hypericin extracts on the affinity and density of the central serotonergic 5HT1A and 5HT2Areceptors. Pharmacopsychiatry, 30 (suppl. 2), 113–116.Google Scholar
Thiele, B., Brink, I. & Ploch, M. (1994) Modulation of cytokine expression by hypericin extract. Journal of Geriatric Psychiatry and Neurology, 7 (suppl. 1), S60–S62.Google Scholar
Tian, J. Z., Zhu, A. H. & Zhong, J. (2003) Afollow-up study on arandomized, single-blind control of King's Brain pills in treatment of memory disorder in elderly people with MCI in a Beijing community. Zhongguo Zhong Yao Za Zhi, 28, 987–991.Google Scholar
Unutzer, J., Klap, R., Sturm, R., et al (2000) Mental disorders and the use of alternative medicine: results from a national survey. American Journal of Psychiatry, 157, 1851–1857.Google Scholar
van Dongen, M., van Rossum, E., Kessels, A., et al (2003) Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. Clinical Epidemiology, 56, 367–376.Google Scholar
Viola, H., Wasowski, C. & Levi de Stein, M. (1995) Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Medica, 61, 213–216.Google Scholar
Vogeler, B. K., Pittler, M. H. & Ernst, E. (1999) The efficacy of ginseng. A systematic review of randomized controlled trials. European Journal of Clinical Pharmacology, 55, 567–575.Google Scholar
Wang, J. L., Patten, S. B. & Russell, M. L. (2001) Alternative medicine use by individuals with major depression. Canadian Journal of Psychiatry, 46, 528–533.Google Scholar
Watanabe, H., Kakihana, M., Ohtsuka, S., et al (1997) Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance. Circulation, 96, 2545–2550.Google Scholar
Werneke, U. (2003) Alternative nutrition therapies in cancer – the evidence. Clinical Nutrition Update, 8, 6–8.Google Scholar
Werneke, U., Earl, J., Seydel, C., et al (2004a) Potential health risks of complementary alternative medicines in cancer patients. British Journal of Cancer, 90, 408–413.Google Scholar
Werneke, U., Horn, O. & Taylor, D. (2004b) How effective is St John's wort? The evidence revisited. Journal of Clinical Psychiatry, 65, 611–617.Google Scholar
Wettstein, A. (2000) Cholinesterase inhibitors and gingko extracts – are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months. Phytomedicine, 6, 393–401.Google Scholar
Whiskey, E., Werneke, U. & Taylor, D. (2001) A systematic review of hypericum perforatum in depression. International Clinical Psychopharmacology, 16, 239–252.Google Scholar
Williams, J. W., Mulrow, C. D. & Chiquette, E. (2000) A systematic review of newer pharmacotherapies for depression in adults. Annals of Internal Medicine, 132, 743–756.Google Scholar
Wolfman, C., Viola, H., Paladini, A., et al (1994) Possible anxiolytic effects of chrysin, acentral benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacology, Biochemistry and Behavior, 47, 1–4.Google Scholar
Wolkowitz, O. M. (1993) Rational polypharmacy in schizophrenia. Annals of Clinical Psychiatry, 5, 79–90.Google Scholar
Zhang, X. Y., Zhou, D. F., Cao, L. Y., et al (2004) The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial. Clinical Psychopharmacology, 24, 83–86.Google Scholar
Ziegler, G., Ploch, M. & Miettinen-Baumann, A. (2002) Efficacy and tolerability of valerian extract L1156 compared with oxazepam in the treatment of non-organic insomnia – a randomized, double-blind, comparative clinical study. European Journal of Medical Research, 25, 480–486.Google Scholar
Zimmerman, R. A. & Thomspon, I. M. Jr (2002) Prevalence of complementary medicine in urologic practice. A review of recent studies with emphasis on use among prostate cancer patients. Urology Clinics of North America, 29, 1–9.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.